Investigation of Predictive Biomarkers in Patients With Advanced BTC Treated With Lenvatinib Plus Pembrolizumab
CHA University
CHA University
Fujian Medical University
Gazi University
University of Pittsburgh
Hospital of Macerata
Intergruppo Melanoma Italiano
Henan Cancer Hospital
University Hospital, Montpellier
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Universitaire Ziekenhuizen KU Leuven
Persephone Biosciences
Vall d'Hebron Institute of Oncology